153P Neoadjuvant therapy with tislelizumab plus chemotherapy followed by concurrent chemoradiotherapy in patients with stage IVa nasopharyngeal carcinoma: A single-arm, phase II trial

The effect of comprehensive treatment for locally advanced nasopharyngeal carcinoma (LANPC) is still unsatisfied, especially for stage IVa NPC. 2 or 3 cycles of neoadjuvant therapy may not be enough. Immunotherapy has been reported to benefit patients with LANPC. Therefore, this study investigated the efficacy and safety of four cycles tislelizumab combined with neoadjuvant chemotherapy in treating stage IVa NPC.